AgomAb Therapeutics NV American Depositary Shares
AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, develops novel disease-modifying therapies for immunology and inflammatory diseases with a focus on chronic fibrotic indications with unmet medical needs. The company's product pipeline includes Ontunisertib (AGMB-129), an oral gastrointestinal-restricted small molecule inhibitor of ALK5 or TGFßR1 for the treatment of Fibrostenos… Read more
AgomAb Therapeutics NV American Depositary Shares (AGMB) - Net Assets
Latest net assets as of September 2025: $146.93 Million USD
Based on the latest financial reports, AgomAb Therapeutics NV American Depositary Shares (AGMB) has net assets worth $146.93 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($165.63 Million) and total liabilities ($18.70 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $146.93 Million |
| % of Total Assets | 88.71% |
| Annual Growth Rate | 64.34% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 43.65 |
AgomAb Therapeutics NV American Depositary Shares - Net Assets Trend (2021–2024)
This chart illustrates how AgomAb Therapeutics NV American Depositary Shares's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for AgomAb Therapeutics NV American Depositary Shares (2021–2024)
The table below shows the annual net assets of AgomAb Therapeutics NV American Depositary Shares from 2021 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $188.08 Million | +24.20% |
| 2023-12-31 | $151.44 Million | +128.59% |
| 2022-12-31 | $66.25 Million | +56.38% |
| 2021-12-31 | $42.36 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to AgomAb Therapeutics NV American Depositary Shares's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 7436400000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $307.26 Million | 163.37% |
| Total Equity | $188.08 Million | 100.00% |
AgomAb Therapeutics NV American Depositary Shares Competitors by Market Cap
The table below lists competitors of AgomAb Therapeutics NV American Depositary Shares ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Tadir-Gan (Precision Products) 1993 Ltd
TA:TDGN
|
$132.47K |
|
Danske Invest Euro Investment Grade-Obligationer
CO:DKIEIGO
|
$132.58K |
|
Archon Corporation
PINK:ARHN
|
$132.68K |
|
All Things Mobile Analytic Inc
PINK:ATMH
|
$132.73K |
|
Cirsa Enterprises SAU
MC:CIRSA
|
$132.23K |
|
Jyske Invest Virksomhedsobligationer
CO:JYIVIRK
|
$132.19K |
|
ARROWSTAR RESOURCES
F:D2E
|
$132.14K |
|
HERBALIFE
MU:HOO
|
$132.12K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in AgomAb Therapeutics NV American Depositary Shares's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 151,435,000 to 188,081,000, a change of 36,646,000 (24.2%).
- Net loss of 46,267,000 reduced equity.
- New share issuances of 97,055,000 increased equity.
- Other factors decreased equity by 14,142,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-46.27 Million | -24.6% |
| Share Issuances | $97.06 Million | +51.6% |
| Other Changes | $-14.14 Million | -7.52% |
| Total Change | $- | 24.20% |
Book Value vs Market Value Analysis
This analysis compares AgomAb Therapeutics NV American Depositary Shares's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently AgomAb Therapeutics NV American Depositary Shares utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -24.60%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.10x
- Recent ROE (-24.60%) is below the historical average (-14.80%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2022 | -12.29% | 0.00% | 0.00x | 1.52x | $-14.77 Million |
| 2023 | -7.52% | 0.00% | 0.00x | 1.13x | $-26.53 Million |
| 2024 | -24.60% | 0.00% | 0.00x | 1.10x | $-65.08 Million |
Industry Comparison
This section compares AgomAb Therapeutics NV American Depositary Shares's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| AgomAb Therapeutics NV American Depositary Shares (AGMB) | $146.93 Million | -12.29% | 0.13x | $132.29K |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |